- Spinal Muscular Atrophy (SMA) is a severe, rare genetic disorder affecting motor nerve cells, often requiring exceptionally expensive life-saving drugs like Risdiplam, Nusinersen, or Onasemnogene abeparvovec (Zolgensma). - A major controversy erupted in Kerala regarding state funding, accessibility, and court interventions for children suffering from SMA seeking exorbitant medical treatment. - The National Policy for Rare Diseases (NPRD) faces implementation hurdles, particularly regarding financial support, limited centers of excellence, and reliance on crowdfunding mechanisms which are often inadequate and slow for high-cost therapies. - Healthcare equity, right to health under Article 21, and state obligations versus budgetary constraints form the core legal and ethical dimensions of the debate. - **National Policy for Rare Diseases (NPRD):** A policy formulated by the Ministry of Health and Family Welfare to address the prevention and treatment of rare disorders, featuring patient categorisation and financial support structures. - **Crowdfunding for Rare Diseases portal:** A dedicated digital platform established by the Union Ministry of Health to bridge funding gaps by facilitating voluntary donations and corporate contributions for rare disease patients. - **Spinal Muscular Atrophy (SMA):** A severe genetic disorder that leads to progressive muscle wasting and weakness due to the loss of motor neurons, requiring extremely expensive lifelong drug therapies. **Introduction** The article explains the controversy in Kerala surrounding the access and state funding for Spinal Muscular Atrophy (SMA) drugs, highlighting the broader national challenges of treating rare diseases, the limitations of the National Policy for Rare Diseases (NPRD), exorbitant drug costs, and the judicial-executive tensions over resource allocation for health equity. **Core Issue and Detailed Points** - Spinal Muscular Atrophy (SMA) is a severe, rare genetic disorder affecting motor nerve cells, often requiring exceptionally expensive life-saving drugs like Risdiplam, Nusinersen, or Onasemnogene abeparvovec (Zolgensma). - A major controversy erupted in Kerala regarding state funding, accessibility, and court interventions for children suffering from SMA seeking exorbitant medical treatment. - The National Policy for Rare Diseases (NPRD) faces implementation hurdles, particularly regarding financial support, limited centers of excellence, and reliance on crowdfunding mechanisms which are often inadequate and slow for high-cost therapies. - Healthcare equity, right to health under Article 21, and state obligations versus budgetary constraints form the core legal and ethical dimensions of the debate. **Key Statutory Bodies, Acts & Concepts** - **National Policy for Rare Diseases (NPRD):** A policy formulated by the Ministry of Health and Family Welfare to address the prevention and treatment of rare disorders, featuring patient categorisation and financial support structures. - **Crowdfunding for Rare Diseases portal:** A dedicated digital platform established by the Union Ministry of Health to bridge funding gaps by facilitating voluntary donations and corporate contributions for rare disease patients. - **Spinal Muscular Atrophy (SMA):** A severe genetic disorder that leads to progressive muscle wasting and weakness due to the loss of motor neurons, requiring extremely expensive lifelong drug therapies.